The bodybuilding peptide conversation is older than the modern peptide market itself. The compounds the “chemical era” bodybuilders of the 90s and 2000s ran - CJC-1295, IGF-1 variants, GHRPs - have been refined, replaced and re-examined in the research literature since. This piece is a neutral research map of what's actually in the modern conversation, what the literature says about each, and where the regulatory line sits.
RUO framing throughout. New-U supplies all compounds named below strictly as laboratory reagents - not for human consumption or athletic application. Every compound discussed here is either WADA-banned in tested federations, restricted under prescription-only schedules, or sold strictly as a research reagent.
| Category | Lifting purpose | Compounds in the conversation |
|---|---|---|
| GH axis / secretagogues | Pulsatile GH release; deep-sleep recovery; lean-mass partitioning | CJC-1295, Ipamorelin, Tesamorelin, GHRP-2/6, MK-677 (oral, not a peptide) |
| Tissue repair | Tendon, ligament, connective tissue recovery from heavy loading | BPC-157, TB-500, GHK-Cu |
| Fat-loss / partitioning | Visceral fat reduction; insulin sensitivity; prep-phase composition | Tesamorelin, AOD-9604, GLP-1 RC-S, GLP-1 RC-T, GLP-1 RC-R |
| Recovery support | Mitochondrial efficiency; metabolic recovery | MOTS-c, Epitalon (sleep / circadian) |
This is the original peptide conversation in bodybuilding, and the most actively researched. CJC-1295 + Ipamorelin remains the most-cited pair in the literature for pulsatile GH release that mimics youthful physiological patterns. The research interest comes from two angles:
Stacked, they produce a stronger and more frequent GH pulse pattern than either alone. The published research (mostly clinical studies in adults with adult-onset GH deficiency or HIV-associated lipodystrophy) documents the mechanism clearly. What the literature doesn't establish is hypertrophy outcomes in trained bodybuilders - that's gym-floor inference, not clinical evidence.
Tesamorelin is the FDA-approved member of this class (approved in 2010 for HIV-associated visceral fat). Its evidence base is therefore stronger than the others - published trials measure body-composition changes directly - but the indication is narrow.
Modern bodybuilding has caught up to what powerlifters and strongmen always knew: hypertrophy is bottlenecked by what the connective tissue can sustain. A torn pec, a blown rotator cuff, a snapped patellar tendon - these end careers faster than any plateau. That's why BPC-157 and TB-500 dominate the recovery conversation.
The research case is documented in our BPC-157 article (soft-tissue mechanism) and TB-500 article (cell migration, broader tissue mobilisation). For bodybuilders specifically the most relevant studies are the rodent Achilles transection model, the equine sports-medicine literature, and the cell-culture work on fibroblast migration.
GHK-Cu sits adjacent - its primary literature is dermal (skin density, collagen) but the same fibroblast-stimulating mechanisms touch tendon and fascia. The field-note observation from a tattoo artist about visibly denser dermis is anecdotally consistent with the connective-tissue research.
The GLP-1 receptor agonist class - GLP-1 RC-S, GLP-1 RC-T, GLP-1 RC-R - has reshaped the cutting conversation entirely. The mechanism (slowed gastric emptying, central appetite suppression, improved insulin sensitivity) is well-characterised in the clinical literature. For bodybuilders the most-discussed risks are lean-mass loss in deep deficits and the question of whether to use them in prep at all - an open debate even among research-curious athletes.
AOD-9604 is a 16-amino-acid fragment of GH that retains lipolytic effects (in animal models) without GH's growth signalling. The clinical-trial evidence in obesity contexts has been mixed; the bodybuilding interest is in targeted fat-loss without IGF-1 elevation.
MOTS-c is the mitochondrial-derived peptide gaining most research interest. Its case is energy metabolism, insulin sensitivity, mitochondrial biogenesis - the systems that underpin recovery between heavy sessions. The literature is mostly mouse-model exercise studies, and the translation to trained humans is open.
For longer-form coverage see our MOTS-c research overview.
Tested-federation warning. Every GH-axis peptide named here (CJC-1295, Ipamorelin, Tesamorelin) is on the WADA Prohibited List under S2. The GLP-1 receptor agonists are restricted prescription medicines. TB-500 is S2. Natural / tested bodybuilding federations (IFPA, BNBF, NPA, INBF) explicitly prohibit all of them. If you compete in any tested format, none of these are usable.
Sealed vials of the full research catalog, independently verified at >99% purity by Janoshik and Freedom Diagnostics. Research use only - not for human consumption. Banned in WADA-tested competition.
Browse the catalog